SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (362)5/21/2008 10:56:17 AM
From: scaram(o)uche  Respond to of 566
 
>> up 24% in the last reporting period <<

OK, so lotsa pukin' shorts all over this stock.

Lehman pointed early to the lymphoma results, and the stock went off like a rocket.

Do we have anything more than this??....

1. R406-sensitive DLBCLs can be identified by their transcriptional profiles (Chen et al., Blood. 2008 Feb 15;111(4):2230-7);

2. R788 has significant clinical activity in B-cell non-Hodgkin's lymphoma (Friedberg et al., James P. Wilmot Cancer Centre, University of Rochester); and

3. the meeting report from Birchenough and buds.



To: scaram(o)uche who wrote (362)6/24/2008 4:08:34 PM
From: scaram(o)uche  Respond to of 566
 
>> short interest was up 24% in the last reporting period and has doubled since mid-December to 6.3m shares <<

Up 10% at last report period, and up 16% in the three reporting periods since that last post. Now stands at 7.3 million shares.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News